Description: Next Science Limited is an Australia-based medical technology company. The Company focuses on the development and commercialization of its Xbio technology to reduce the impact of biofilm-based infections in human health. Its products include Bactisure Surgical Lavage, BlastX Antimicrobial Wound Gel, TorrentX Wound Wash, SurgX Sterile Antimicrobial Wound Gel for Surgical Site Infections and Acne Treatment. The SurgX is a surgical gel designed to help reduce superficial surgical site infections (SSIs) and protect wound tissue to facilitate natural healing. Its Bactisure is designed to remove structurally resistant forms of bacteria (biofilm) through physical deconstruction of the extracellular polymeric substance (EPS) matrix, making bacteria more susceptible to traditional antibiotics and the body’s normal defense mechanisms. BlastX is an antimicrobial wound gel and deconstructs the bacterial biofilm, the gel envelops and eliminates the bacteria.
Home Page: www.nextscience.com
NXS Technical Analysis
The Zenith Building, Tower A
Chatswood,
NSW
2067
Australia
Phone:
61 2 8607 5126
Officers
| Name | Title |
|---|---|
| Ms. Judith Mitchell M.B.A. | MD, CEO & Exec. Director |
| Dr. Matthew Franco Myntti | Founder & CTO |
| Ms. Jacqueline Butler CA (ICAEW) | Chief Financial Officer |
| Mr. Jon Swanson | Chief Operating Officer |
| Mr. Michael Morello | VP of Sales |
| Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 9.0171 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.0831 |
| Price-to-Sales TTM: | 14.2932 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |